## Injectable GLP-1 Receptor Agonist (RA) and Long-Acting GIP/GLP-1 RA Quick Reference Quantity Guide



Generic name	Brand name	Manufacturer	Preparation strength	Preparation presentation pre-filled (PF)	Pack size	Frequency of administration	1 month supply	Pen needle Rx required?
Licensed for	use in Type 2 [	Diabetes Mellitus o	nly					
Semaglutide BNF	Ozempic®	Novo Nordisk Ltd	0.25mg/0.19ml SPC	1.5ml PF pen	1 pen	Weekly	1 pen = 4 doses	No, 4 NovoFine Plus® needles included
			0.5mg/0.37ml SPC	1.5ml PF pen	1 pen	Weekly	1 pen = 4 doses	
			1mg/0.74ml SPC	3ml PF pen	1 pen	Weekly	1 pen = 4 doses	
Dulaglutide BNF	Trulicity®	Eli Lilly and Company Ltd	0.75mg/0.5ml SPC	0.5ml PF pen	4 pens	Weekly (single use pen)	4 pens (1 pack) = 4 doses	No, pens come with permanently attached needle
			1.5mg/0.5ml SPC	0.5ml PF pen	4 pens	Weekly (single use pen)	4 pens (1 pack) = 4 doses	
			3mg/0.5ml SPC	0.5ml PF pen	4 pens	Weekly (single use pen)	4 pens (1 pack) = 4 doses	
			4.5mg/0.5ml SPC	0.5ml PF pen	4 pens	Weekly (single use pen)	4 pens (1 pack) = 4 doses	
<u>Liraglutide</u> BNF	Diavic®	Sun Pharma UK Ltd	6mg/ml	3ml PF pen	2 or 3	0.6mg Daily	1 pen = 30 doses	Yes
			SPC		pens	1.2mg Daily	2 pens = 30 doses	
						1.8mg Daily	3 pens = 30 doses	
	Zegluxen®	Zentiva Pharma UK Ltd	6mg/ml	3ml PF pen	2 or 3	0.6mg Daily	1 pen = 30 doses	Yes
			SPC		pens	pens 1.2mg Daily	2 pens = 30 doses	
						1.8mg Daily	3 pens = 30 doses	

## Injectable GLP-1 Receptor Agonist (RA) and Long-Acting GIP/GLP-1 RA Quick Reference Quantity Guide



Generic	Brand	Manufacturer	Preparation	Preparation	Pack	Frequency of	1 month supply	Pen
name	name		strength	presentation	size	administration		needle Rx
				pre-filled (PF)				required?
Licensed for u	ıse in Type 2	Diabetes Mellitus a	nd Weight Man	agement				
Tirzepatide BNF	Mounjaro KwikPen®	Eli Lilly and Company Ltd	2.5mg/0.6ml	2.4ml PF pen	1 pen	Weekly	1 pen = 4 doses	Yes
			SPC					
			5mg/0.6ml	2.4ml PF pen	1 pen	Weekly	1 pen = 4 doses	
			SPC					
			7.5mg/0.6ml	2.4ml PF pen	1 pen	Weekly	1 pen = 4 doses	
			SPC					
			10mg/0.6ml	2.4ml PF pen	1 pen	Weekly	1 pen = 4 doses	
			SPC					
			12.5mg/0.6ml	2.4ml PF pen	1 pen	Weekly	1 pen = 4 doses	
			SPC					
			15mg/0.6ml	2.4ml PF pen	1 pen	Weekly	1 pen = 4 doses	
			SPC					

**NOTE:** tirzepatide (Mounjaro®) has a <u>RED</u> Leicester, Leicestershire & Rutland (LLR) formulary status for weight management and therefore is not commissioned for prescribing for weight loss in any NHS setting across LLR, except via commissioned LLR weight management services. For further details, see <u>LLR Position Statement Tirzepatide (Mounjaro®) For Obesity Management</u>. Prescribing of tirzepatide (Mounjaro®) for Type 2 Diabetes Mellitus in primary care can continue in line with existing NICE guidance and local formulary arrangements.